FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Akums Drugs and Pharmaceuticals IPO and Brainbees Solutions (Firstcry) IPO.
Akums Drugs and Pharmaceuticals IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Brainbees Solutions (Firstcry) IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | ICICI Securities Limited Axis Bank Limited Citigroup Global Markets India Private Limited Ambit Private Limited |
Kotak Mahindra Capital Company Limited Morgan Stanley India Company Pvt Ltd Bofa Securities India Limited Jm Financial Limited Avendus Capital Pvt Ltd |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Akums Drugs and Pharmaceuticals IPO is up to ₹1,856.74 Cr whereas the issue size of the Brainbees Solutions (Firstcry) IPO is up to ₹4,193.73 Cr. The final issue price of Akums Drugs and Pharmaceuticals IPO is ₹679.00 per share and of Brainbees Solutions (Firstcry) IPO is ₹465.00 per share.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |
---|---|---|
Face Value | ₹2 per share | ₹2 per share |
Issue Price (Lower) | ₹646.00 per share | ₹440.00 per share |
Issue Price (Upper) | ₹679.00 per share | ₹465.00 per share |
Issue Price (Final) | ₹679.00 per share | ₹465.00 per share |
Discount (Retail) | ||
Discount (Employee) | ₹64.00 per share | ₹44.00 per share |
Market Lot Size | 22 shares | 32 shares |
Fresh Issue Size | 1,00,14,727 shares | 3,58,27,957 shares |
Fresh Issue Size (Amount) | up to ₹680.00 Cr | up to ₹1,666.00 Cr |
OFS Issue Size | 1,73,30,435 shares | 5,43,59,733 shares |
OFS Issue Size (Amount) | up to ₹1,176.74 Cr | up to ₹2,527.73 Cr |
Issue Size Total | 2,73,45,162 shares | 9,01,87,690 shares |
Issue Size Total (Amount) | up to ₹1,856.74 Cr | up to ₹4,193.73 Cr |
Akums Drugs and Pharmaceuticals IPO opens on Jul 30, 2024, while Brainbees Solutions (Firstcry) IPO opens on Aug 06, 2024. The closing date of Akums Drugs and Pharmaceuticals IPO and Brainbees Solutions (Firstcry) IPO is Aug 01, 2024, and Aug 08, 2024, respectively.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |
---|---|---|
Anchor Bid Date | Jul 29, 2024 | Aug 05, 2024 |
Issue Open | Jul 30, 2024 | Aug 06, 2024 |
Issue Close | Aug 01, 2024 | Aug 08, 2024 |
Basis Of Allotment (Tentative) | Aug 02, 2024 | Aug 09, 2024 |
Initiation of Refunds (Tentative) | Aug 05, 2024 | Aug 12, 2024 |
Credit of Share (Tentative) | Aug 05, 2024 | Aug 12, 2024 |
Listing date (Tentative) | Aug 06, 2024 | Aug 13, 2024 |
Anchor Lockin End date 1 | Sep 01, 2024 | Sep 08, 2024 |
Anchor Lockin End date 2 | Oct 31, 2024 | Nov 07, 2024 |
Akums Drugs and Pharmaceuticals IPO P/E ratio is , as compared to Brainbees Solutions (Firstcry) IPO P/E ratio of -69.91.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Akums Drugs and Pharmaceuticals Limited Financial Information (Restated Consolidated)Akums Drugs and Pharmaceuticals Limited's revenue increased by 13.81% and profit after tax (PAT) dropped by -99.19% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Brainbees Solutions Limited Financial Information (Restated Consolidated)Brainbees Solutions Limited's revenue increased by 14.72% and profit after tax (PAT) rose by 33.85% between the financial year ending with March 31, 2024 and March 31, 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 84.94% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | -69.91 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹24141.75 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 0.11%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 3.37%% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹-6.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | -0.57% | -8.65%% |
In the Akums Drugs and Pharmaceuticals IPO retail investors (RII) are offered 27,12,424 shares while in Brainbees Solutions (Firstcry) IPO retail investors are offered 27,12,424 shares. Qualified institutional buyers (QIB) are offered 81,37,276 shares in Akums Drugs and Pharmaceuticals IPO and 2,70,36,953 shares in Brainbees Solutions (Firstcry) IPO.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |
---|---|---|
Anchor Investor Reserveration | 1,22,05,912 shares | 4,05,55,428 shares |
Market Maker Reserveration | ||
QIB | 81,37,276 shares | 2,70,36,953 shares |
NII | 40,68,637 shares | 1,35,18,476 shares |
RII | 27,12,424 shares | 90,12,317 shares |
Employee | 2,43,902 shares | 71,258 shares |
Others | ||
Total | 1,51,62,239 shares | 4,96,39,004 shares |
Akums Drugs and Pharmaceuticals IPO subscribed 63.44x in total, whereas Brainbees Solutions (Firstcry) IPO subscribed 12.22x.
Akums Drugs and Pharmaceuticals IPO | Brainbees Solutions (Firstcry) IPO | |
---|---|---|
QIB (times) | 90.09x | 19.30x |
NII (times) | 42.10x | 4.68x |
Big NII (times) | 47.43x | 5.32x |
Small NII (times) | 31.45x | 3.39x |
RII (times) | 20.80x | 2.31x |
Employee (times) | 4.14x | 6.57x |
Other (times) | ||
Total (times) | 63.44x | 12.22x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|